Nuclear ALG-2 Protein Interacts with Ca\(^{2+}\) Homeostasis Endoplasmic Reticulum Protein (CHERP) Ca\(^{2+}\)-dependently and Participates in Regulation of Alternative Splicing of Inositol Trisphosphate Receptor Type 1 (IP\(_{3}\)R1) Pre-mRNA*\(^{\dagger}\)

Kanae Sasaki-Osugi\(^{1}\), Chiaki Imoto, Terunao Takahara, Hideki Shibata, and Masatoshi Maki\(^{2}\)

From the Department of Applied Molecular Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

**Background:** ALG-2 is present both in the cytoplasm and nucleus, but little is known about its nuclear function. ALG-2 interacts with the SR superfamily protein CHERP and accumulates at nuclear speckles in a Ca\(^{2+}\) -dependent manner. Results: ALG-2 and CHERP participate in alternative splicing.

**Conclusions:** We propose a new role of ALG-2 and CHERP in post-transcriptional processing in the nucleus.

The intracellular Ca\(^{2+}\) signaling pathway is important for the control of broad cellular processes from fertilization to cell death. ALG-2 is a Ca\(^{2+}\)-binding protein that contains five serially repeated EF-hand motifs and interacts with various proteins in a Ca\(^{2+}\)-dependent manner. Although ALG-2 is present both in the cytoplasm and in the nucleus, little is known about its nuclear function. Ca\(^{2+}\)-homeostasis endoplasmic reticulum protein (CHERP) was first identified as an endoplasmic reticulum protein that regulates intracellular Ca\(^{2+}\) mobilization in human cells, but recent proteomics data suggest an association between CHERP and spliceosomes. Here, we report that CHERP, containing a Pro-rich region and a phosphorylated Ser/Arg-rich RS-like domain, is a novel Ca\(^{2+}\)-dependent ALG-2-interactive target in the nucleus. Immunofluorescence microscopic analysis revealed localization of CHERP to the nucleoplasm with prominent accumulation at nuclear speckles, which are the sites of storage and modification for pre-mRNA splicing factors. Live cell time-lapse imaging showed that nuclear ALG-2 was recruited to the CHERP-localizing speckles upon Ca\(^{2+}\) mobilization. Results of co-immunoprecipitation assays revealed binding of CHERP to a phosphorylated form of RNA polymerase II. Knockdown of CHERP or ALG-2 in HT1080 cells resulted in generation of alternatively spliced isoforms of the inositol 1,4,5-trisphosphate receptor 1 (IP\(_{3}\)R1) pre-mRNA that included exons 41 and 42 in alternatively spliced isoforms of the inositol 1,4,5-trisphosphate receptor type 1 (IP\(_{3}\)R1) pre-mRNA and provide new insights into post-transcriptional regulation of splicing variants in Ca\(^{2+}\) signaling pathways.

ALG-2 (apoptosis-linked gene 2, also named programmed cell death 6; gene name, PDCD6), a 22-kDa Ca\(^{2+}\)-binding protein, was identified by a method to select genes involved in apoptosis of murine cells (1). Although accumulating data indicate involvement of ALG-2 in apoptosis and cancer in mammals (2–6), details of its physiological functions at the molecular level have remained unclear. ALG-2 has five serially repeated EF-hand motifs (penta-EF-hand and a penta-EF-hand domain) (7, 8) and interacts with various proteins, including ALIX (9, 10), Sec31A (11, 12), and PLSCR3 (see Refs. 13 and 14 and references therein). Most ALG-2-binding proteins contain a proline-rich region (PRR), through which they interact with a Ca\(^{2+}\)-bound form of ALG-2. Identification of ALG-2-binding sites in ALIX (15, 16), Sec31A (17), and PLSCR3 (13) allowed us to determine two different types of ALG-2-binding motifs as follows: type 1, PYP(Y)XP (where X, variable; n = 4 in ALIX and PLSCR3-ABS1); type 2, PXPFX (X, variable; Sec31A and PLSCR3-ABS2). We recently developed a method to screen novel ALG-2-interacting proteins using these motifs in PRRs for an in silico search, followed by far Western blot analysis of GFP-fused PRR proteins (18). In this study, we selected one of the previously obtained positive candidates, named CHERP (Ca\(^{2+}\)-homeostasis endoplasmic reticulum protein), for further characterization as an ALG-2-interacting protein and investigated its biological functions.

---

*This work was supported in part by Grant-in-aid for Scientific Research (B) Project No. 23380056 from the Japan Society for the Promotion of Science (to M. M.) and Grant-in-aid from the Japan Society for the Promotion of Science (to K. S.).

\(^{\dagger}\)Recipient of a Japan Society for the Promotion of Science research fellowship for young scientists (DC2).

\(^{\dagger}\)To whom correspondence should be addressed. E-mail: mmaki@agr.nagoya-u.ac.jp.

---

The abbreviations used are: PRR, proline-rich region; FW, far Western; IP\(_{3}\)R1, inositol 1,4,5-trisphosphate receptor type 1; pAb, polyclonal antibody; qPCR, quantitative PCR; RRM, RNA recognition motif; TG, thapsigargin; WB, Western blotting; ER, endoplasmic reticulum; CHERP, Ca\(^{2+}\)-homeostasis endoplasmic reticulum protein; CID, C-terminal domain; ODI, C-terminal domain-interacting domain; pol, polymerase; SERCA, sarcoplasmic/endo-plasmic reticulum Ca\(^{2+}\)-ATPase; FL, full-length; ROI, region of interest; NC, negative control; HEL, human erythroleukemia; IP, immunoprecipitation; CIAP, calf intestine alkaline phosphatase; NLS, nuclear localization signal.

---

\(^{#}\)This article contains supplemental Movies S1–S4.
Nuclear ALG-2 and CHERP in Alternative Splicing

CHERP was first identified as a target of a monoclonal antibody that blocked 1,4,5-trisphosphate (IP₃)-induced Ca²⁺ release from the isolated endoplasmic reticulum (ER) (19), and its cDNA was immunoscreened from a cDNA expression library of human erythroleukemia (HEL) cells (20). CHERP was shown to co-localize with IP₃ receptors throughout the cytoplasmic and perinuclear regions in HEL cells and in Jurkat cells (20, 21). Antisense-mediated knockdown of CHERP impaired intracellular Ca²⁺ mobilization and cell growth and proliferation. A recent study has indicated that CHERP interacts with ryanoide receptor 1 (RyR1) and that knockdown of CHERP affects Ca²⁺ release from the ER (22).

However, proteomics analyses showed that CHERP was present in the fractions of 17 S U2 small nuclear ribonucleoproteins (23) and nuclear speckles (24), which are storage and assembly sites for splicing factors. Lin-Moshier et al. (25) re-investigated subcellular localization of CHERP by immunostaining with a specific antibody and by fluorescence microscopic analysis of GFP-fused CHERP, and they identified nuclear localization signals and concluded that CHERP exclusively localizes to the nucleus, including nuclear speckles. Nuclear function of CHERP, however, has not been demonstrated yet. There is a segment of Arg-Ser dipeptide repeats near the C terminus of CHERP. Ser/Arg-rich (SR) proteins containing a region of Arg-Ser dipeptide repeats and RNA recognition motifs (RRMs) constitute a family of splicing regulatory factors (26–28). RS domains of SR proteins and RNA recognition motifs (RRMs) constitute a family of splicing regulatory factors. RS domains of SR proteins are phosphorylated at numerous serine residues, and the phosphorylation is thought to play important roles in broad phenomena of RNA processing, including alternative splicing (29). Phosphorylation of the RS-like domain of CHERP, however, has not been reported yet.

In this report, we show that ALG-2 interacts with CHERP in a Ca²⁺-dependent manner through at least two sites containing ALG-2-binding motif-like sequences in the PRR. ALG-2 was shown to be recruited to CHERP-positive nuclear speckles upon Ca²⁺ mobilization in living cells by time-lapse imaging of fluorescent protein-fused proteins. Depletion of CHERP or ALG-2 by the RNA interference method affected alternative splicing of the pre-mRNA of inositol 1,4,5-trisphosphate receptor 1 (IP₃R1). Association of CHERP with IP₃R1 RNA was demonstrated. These findings suggest that CHERP has a new role as an SR superfamily protein and regulates alternative splicing of IP₃R1 pre-mRNA. ALG-2 may also participate in the post-transcriptional regulation of IP₃R1 pre-mRNA at least in part by interacting with CHERP.

MATERIALS AND METHODS

Antibodies and Reagents—The following antibodies were purchased: mouse anti-GFP monoclonal antibody (mAb) clone B-2 (sc-9996), rabbit anti-FBP21 (WBP4) polyclonal antibody (pAb) (N-16; sc-84249), mouse anti-GAPDH mAb (clone 6C5, sc-32233), and rabbit anti-pol II pAb (N-20, sc-899) from Santa Cruz Biotechnology (Santa Cruz, CA); mouse anti-calnexin mAb (clone 37) from BD Biosciences; rabbit anti-apoptosis-inducing factor pAb (ab1998) and mouse anti-SF3A2 mAb (ab77800) from Abcam (Cambridge, UK); mouse anti-CHERP mAb (clone 2H5) from Abnova (Taipei, Taiwan); mouse anti-SC35 mAb (clone S4045) from Sigma; and mouse mAb against pan-SR proteins (clone 1H4) from Invitrogen. Affinity purification of rabbit anti-human ALG-2 pAb using the recombinant ALG-2 protein immobilized on an N-hydroxysuccinimide column (GE Healthcare) was described previously (12). Anti-human ALG-2 antiserum was also raised in a goat using glutathione S-transferase (GST)-fused ALG-2 as an antigen, and the antibody was similarly affinity-purified (18). Anti-human CHERP antiserum was raised in rabbits using a CHERP C-terminal region (820–916 amino acids) protein (CHERPct) that was fused with GST, and specific antibodies were affinity-purified using CHERPct that was fused with maltose-binding protein. Protease inhibitors 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (Pefabloc) and l-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) were from Merck and the Peptide Institute (Osaka, Japan), respectively. Thapsigargin, an inhibitor of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA), was from Wako (Osaka, Japan).

Plasmid Construction—Human CHERP cDNA (clone MHS1011-76655) was purchased from Open Biosystems (Lafayette, CO), and the cDNA of full-length (FL) was inserted between the XhoI and the SalI site of pEGFP-C1 (Clontech) or pSGFP2-C1 kindly provided by Dr. Wada, Fukushima Medical University School of Medicine, who constructed the vector according to Ref. 30) using an In-Fusion Advantage PCR cloning Kit (Clontech). To construct plasmids for expression of GFP-fused CHERP deletion mutants designated GFP-CHERP ΔCID and GFP-CHERP ΔRS, cDNA fragments lacking CID (149–293 amino acids) or RS (725–822 amino acids) were amplified by the overlap PCR method using pEFGP-C1/CHERP FL as a template DNA and with two different pairs of specific primers, and each fragment was inserted into the XhoI/Sall site of pEGFP-C1. To construct pEFGP-C1/CHERP ΔPRR, a cDNA fragment encoding the PRR of CHERP (352–705 amino acids) was removed from pEFGP-C1/CHERP FL by cleavage at two EcoRV sites generated by site-directed mutagenesis, followed by self-ligation. Construction of pSGFP2-C1/ALG-2 and pEFGP-C3/CHERP PRR was described previously (17, 18). Other constructs were obtained by the PCR-based subcloning method with specific primers.

pmCherry-C1/ALG-2 was constructed by insertion of an EcoRI/XhoI fragment of pFLAG-ALG-2W/T/RNAiR (31) into the EcoRI/Sall site of pmCherry-C1 (Clontech). The nuclear Ca²⁺-sensor vector CMV-NLS-R-GECo (32) was obtained from the nonprofit plasmid repository Addgene (plasmid 32462).

Cell Culture and DNA Transfection—HEK293T, HeLa SS4 (subcloned HeLa cells, see Ref. 12), and HT1080 cells were cultured in DMEM (Nissui, Tokyo, Japan) supplemented with 4 mM glutamine, 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 °C under humidified air containing 5% CO₂. Cells were seeded and cultured for 1 day, and then they were transfected with the expression plasmid DNAs by the conventional calcium phosphate precipitation method for HEK293T cells or by using FuGENE 6 (Promega, Madison, WI) for HeLa and HT1080 cells.

Far Western Blot Analysis—Far Western (FW) blot analysis with biotin-labeled ALG-2 was performed as described previously (18, 33). Briefly, HEK293T cells that had been transfected
with pEGFP-C1/CHERP FL or its deletion mutants were lysed with lysis buffer T (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1.5 mm MgCl₂, and 0.2% Triton X-100 containing protease inhibitors). The cleared lysate was subjected to immunoprecipitation with GFP-TrapA (ChromTek, Martinsried, Germany), followed by Western blot (WB) and FV analyses.

Subcellular Fractionation and Immunoprecipitation—HEK293T cells were suspended in a hypotonic buffer (10 mm HEPES-KOH, pH 7.6, 10 mm KCl, 1.5 mm MgCl₂, 5 mm 2-mercaptoethanol) containing protease inhibitors (0.1 mm Pefabloc, 3 μg/ml leupeptin, 1 μM E-64, 1 μM pepstatin, and 0.1 mM phenylmethylsulfonyl fluoride) and homogenized by passing 25 times through a 26-gauge needle. After adding a solution of NaCl to 0.15 M, the homogenate was fractionated by differential sucrose centrifugation at 4 °C. Pellets of 600 through a 26-gauge needle. After adding a solution of NaCl to 0.15 M, the homogenate was fractionated by differential sucrose centrifugation at 4 °C. Pellets of 600

**TABLE 1**

| Protein or RNA names (gene names) | Isoforms | Primer sequences |
|-----------------------------------|----------|-----------------|
| ALG-2 (PDCD6)                    | ΔE90     | 5'-tgataaaacagggagggagt3'- |
| CHERP               | ΔE90/41  | 5'-cacaagctccctacctctg3'- |
| GAPDH               | ΔE90/41/42 | 5'-tgactaaccaagggaaacc-3' |
| 18S rRNA            | All      | 5'-tctgacccataaagaagc-3' |
| Histone H3 (HIST2H3)  |          | 5'-tgagagaaggtttgaggg-3' |
| IP₃R1 (ITPR1)       |          | 5'-tcgctcagggtttgaggg-3' |

| Protein or RNA names (gene names) | Isoforms | Primer sequences |
|-----------------------------------|----------|-----------------|
| ALG-2 (PDCD6)                    | ΔE90     | 5'-tgataaaacagggagggagt3'- |
| CHERP               | ΔE90/41  | 5'-cacaagctccctacctctg3'- |
| GAPDH               | ΔE90/41/42 | 5'-tgactaaccaagggaaacc-3' |
| 18S rRNA            | All      | 5'-tctgacccataaagaagc-3' |
| Histone H3 (HIST2H3)  |          | 5'-tgagagaaggtttgaggg-3' |
| IP₃R1 (ITPR1)       |          | 5'-tcgctcagggtttgaggg-3' |

**RNA Interference and RNA Sample Preparation**—All siRNAs (siCHERP.1, 5'-gguauagcaagagcuucuag-3'; siCHERP.2, 5'-gguauagcaagagcuucuag-3'; siALG-2.1, 5'-ggaaagguacggcagtcg-3'; siALG-2.4, 5'-ggaaagguacggcagtcg-3'; negative control, 5'-ggaaagguacggcagtcg-3'; sequences of sense strand shown; deoxyribonucleotides indicated by uppercase letters) were purchased from Integrated DNA Technologies (Corvalia, IA). HT1080 cells were transfected with 10 nm siRNA duplexes targeting CHERP, ALG-2, or negative control siRNA using RNAiMAX (Invitrogen) according to the reverse transfection method described in the manufacturer’s instructions. Cells were harvested 72 h after siRNA transfection. Total RNA was prepared with Sepasol Super G (Nacalai Tesque, Kyoto, Japan), and genome DNA was digested with 20 units/ml DNase (Nippon Gene, Tokyo, Japan).

**Quantitative RT-PCR**—RT-PCR and quantitative PCR (qPCR) were performed using a PrimeScript™ RT reagent kit (Perfect Real Time, RR037A, Takara Bio) and FastStart Essential DNA Green Master (Roche Applied Science), respectively. Reverse transcription products were analyzed by LightCycler® Nano (Roche Applied Science) using specific primers for IP₃R1 isoforms (Table 1). GAPDH mRNA was used as an internal control for all qPCRs except for RNA immunoprecipitation assay. Ratios among transcript levels of individual IP₃R1 isoforms were obtained by dividing each expression level by the sum of all isoforms.

**RNA Immunoprecipitation Assay**—RNA immunoprecipitation was performed using an RNA immunoprecipitation assay kit (MBL, Nagoya, Japan) according to the manufacturer’s instructions. Briefly, HEK293T cells were lysed in the provided lysis buffer supplemented with 1.5 mm dithiothreitol, 80 units/ml RNase inhibitor (RNaseOUT™, Invitrogen), and protease inhibitors. An aliquot (2%) of the supernatant obtained by centrifugation at 12,000 × g was used for total RNA isolation. The remainder was incubated at 4 °C for 3 h with protein G-Sepharose beads (GE Healthcare) that were preincubated with rabbit anti-CHERP pAb or control rabbit IgG. After washing with the buffer four times, RNA in the immunoprecipitates was purified and subjected to RT-PCR and qPCR analyses using primers for the cDNAs of IP₃R1, GAPDH, and histone H3.
**RESULTS**

**ALG-2 Interacts with CHERP in a Ca\(^{2+}\)-dependent Manner**—We previously reported that the GFP-fused PRR of CHERP showed a positive signal in FW blot analysis with biotin-labeled ALG-2 (18), but interaction between endogenous CHERP and ALG-2 remains to be established. Because there have been conflicting reports about the subcellular localization of CHERP (ER or nucleus), we first investigated the subcellular distribution of CHERP. As shown in Fig. 1A, biochemical cell fractionation of HEK293T cells by the differential centrifugation method revealed that WB signals of CHERP were mostly present in the 600 \(\times\) g (P\(_{0.6}\)) fraction in a manner similar to that of the nuclear marker WW domain-binding protein 4 (WBP4). After centrifugation at 10,000 \(\times\) g for 10 min at 4 °C, the supernatant (Input) was treated with RNase A (10 \(\mu\)g/ml) and supplemented with 5 mM EGTA or 10 \(\mu\)M CaCl\(_2\) (C). Each sample was subjected to immunoprecipitation by incubating first with mouse IgG (negative control, ctrl) or anti-CHERP mAb for 1 h at 4 °C and then with magnetic beads carrying protein G overnight. After the beads had been collected and washed, immunoprecipitated proteins (IP products) were subjected to SDS-PAGE using 12.5% gel, transferred to a sheet of PVDF membrane, which was cut into halves (high and low molecular weight), and subjected to WB with anti-CHERP mAb (upper panel) and with anti-ALG-2 pAb (lower panel). Single and double asterisks indicate light and heavy chains of IgG, respectively. The relative amount of cleared cell lysate proteins (Input) used for analysis of IP products was 1.5%. Representative data obtained from three (A), two (B), and four (C) independent experiments are shown.

---

*(HIST2H3) (Table 1). All RNA levels were normalized to 18 S rRNA.*
to further search for ALG-2-binding sites. The N-terminal end
munoprecipitated with CHERP was increased by increasing the
deletion mutant (Fig. 2b, lane 6), and then the supernatant was subjected to
co-immunoprecipitation assay. As shown in Fig. 1B, an ALG-2-specific band was detected in the immunoprecipitation (IP) product with an antibody against CHERP (anti-CHERP) in the presence of 10 μM CaCl2 but not in the presence of 5 mM EGTA. No ALG-2 bands were observed in the case of control IgG in either condition, IgG bands of light and heavy chains (IgGf and IgGh) were detected with similar intensities in the two conditions. Faster migrating bands detected with anti-CHERP (upper panel) probably correspond to degradation products of CHERP.

As shown in Fig. 1C, the amount of ALG-2 that was co-immunoprecipitated with CHERP was increased by increasing the concentration of supplemented CaCl2 from none (lane 3) to 100 μM (lane 6). Under the conditions used, although more than 80% of input CHERP was immunoprecipitated with the antibody (data not shown), ~1–3% of input ALG-2 was co-immunoprecipitated (lane 1, input, 1.5%). Although the increase of ALG-2 binding at higher concentrations of CaCl2 (Fig. 1C, lanes 5 and 6) is reproducible, the degree was variable from experiment to experiment, and the detected signal of ALG-2 at the lowest supplementation of CaCl2 (Fig. 1C, lane 4, 1 μM) was comparable with that without supplementation (lane 3). The apparent Ca2+- dependency at the lower Ca2+ concentration range might have been partly due to a trace of Ca2+ derived from cells or from the lysis buffer and partly due to the complex that had been already formed Ca2+-dependently within the nucleus, because addition of 5 mM EGTA (Fig. 1C, lane 2) caused disappearance of the ALG-2 band.

Multiple ALG-2-binding Sites in the PRR of CHERP—In addition to the PRR, CHERP has four distinct regions with sequences similar to those designated SURP (also named SWAP), CID (RNA polymerase II C-terminal domain-interacting domain), RS (Arg-Ser dipeptide repeats), and G-patch. The PRR of CHERP has a sequence, P565PPYPHRFDYP574, that is in accordance with the type 1 ALG-2-binding motif (conserved residues underlined).

Ser dipeptide repeats), and G-patch. The PRR of CHERP has a
polymerase II C-terminal domain-interacting domain), RS (Arg-
Ser dipeptide repeats), and G-patch. The PRR of CHERP has a
sequence, P565PPYPHRFDYP574, that is in accordance with the
type 1 ALG-2-binding motif (conserved residues underlined).

To obtain evidence that this sequence is essential for CHERP to
interact with ALG-2, we first constructed GFP fusion expres-
sion vectors encoding the FL CHERP protein and a deletion
mutant of this region (Fig. 2b, ΔCID, lane 2) and deletion of the RS
domain (ΔRS, lane 4) retained binding abilities, but the PRR-
deletion mutant (ΔPRR, lane 3) did not, we focused on the PRR
for further search for ALG-2-binding sites. The N-terminal end
of the PRR has a unique Pro-Ala repeat sequence (P554TPP-
PAPPPAPAPAPAPAIPP372), but deletion of this sequence had lit-
tle effect on the binding (Fig. 2b, Δ354–372, lane 5). Although
it is not in accordance with the previously proposed type 2 motif
b (PXPGF), the PRR has a similar sequence of P561PPPHGF619. To
determine the importance of this type 2 motif-like sequence for
ALG-2 binding, we further deleted this region (Δ557–585/ Δ613–623) or replaced Phe619 with Ser (Δ557–585/F619S) in addition to the deletion of type 1 motif-like sequence (Δ557–585).

These mutations caused a significant decrease in signal intensity in FW, but faint bands still remained (Fig. 2b, lanes 7 and 8). As shown in the right panels in Fig. 2b, compared with GFP-PRR, intensity of FW signals of GFP-PRR decreased by truncation of the C-terminal region containing the type 2 motif-like sequence (GFP(343–599)), or FW signals disappeared in GFP(343–462). Because signal intensity of GFP(550–636) was weaker than that of GFP PRR (Fig. 2b, lane 10 versus lane 13), there may exist at least one more important site in either side of 550–636 for ALG-2-binding.

CHERP Is Present in the Nucleus and Concentrated at Nuclear Speckles—We performed fluorescence microscopic analysis of GFP-CHERP mutant proteins expressed in HeLa cells. Although the full-length and the mutants deleted in CID or PRR showed exclusively nuclear localization, a deletion mutant of RS (GFP-CHERP ΔRS) showed cytoplasmic as well as nuclear localization (Fig. 2c). All cytoplasmic punctate signals of GFP-CHERP ΔRS merged with those of ALG-2 and partially overlapped with those of Sec31A, a component of COPII (Fig. 2d). To investigate the subnuclear distribution of endogenous CHERP, we carried out triple immunostaining of HeLa cells with rabbit anti-CHERP pAb, goat anti-ALG-2 pAb, and mouse mAb against SC35 (alternatively called SRSF2), which is a splicing factor that mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3′ splice site (26), and which is a well known marker of nuclear speckles (34). Effects of pre-permeabilization with digitonin before fixation were also investigated. Immunofluorescence signals of CHERP were observed in the nucleus (Fig. 3), and the pre-permeabilization had little effect (b and f). Dense signals of CHERP in the nucleus partially overlapped with those for SC35 (Fig. 3, c and g), indicating partial localization of CHERP at nuclear speckles. Nuclear ALG-2 signals were rather uniformly diffused in the nucleoplasm compared with those of CHERP without pre-permeabilization (Fig. 3, a) but became punctate by pre-permeabilization with digitonin (e). ALG-2 Transiently Accumulates at Nuclear Speckles in Response to Ca2+-Mobilization—By live-cell imaging, ALG-2 has been shown to translocate to the Sec31A-positive ER exit sites transiently in response to Ca2+-mobilization (17, 35). We previously noticed the appearance of ALG-2 puncta in the nucleus but left them uncharacterized (17). Now we know that ALG-2 binds to CHERP Ca2+-dependently, we have decided to re-investigate whether fluorescent protein-fused ALG-2 in living cells responds to thapsigargin (a SERCA pump inhibitor and Ca2+-elevating agonist) and accumulates at nuclear speckles by co-localizing with CHERP. First, we expressed SGFP2-ALG-2 and NLS-R-GECo, which is a nuclear Ca2+-indicator protein (32). Thapsigargin (TG) administration resulted in
redistribution of cytoplasmic and nuclear ALG-2 concomitantly with an increase in NLS-R-GECO signals (Fig. 4, panels a–d, and B, and supplemental Movie S1). Fluorescent signals of SGFP2-ALG-2 at nucleoplasmic puncta were increased transiently (ROI-1 and ROI-2), whereas the signals remained constant in the nucleoplasm (ROI-3) and were decreased in the
nucleolus (ROI-4). Next, cells expressing SGFP2-CHERP and mCherry-ALG-2 at low to middle levels were used for time-lapse analysis. Like SGFP2-ALG-2, mCherry-ALG-2 localized throughout the cytoplasm and nucleus, uniformly in the nucleoplasm outside of nucleoli before stimulation with thapsigargin (Fig. 4C, panel f). However, SGFP2-CHERP localized within the nucleoplasm and accumulated at nuclear speckles (Fig. 4C, panels e and g) in a manner similar to that for immunostaining of fixed cells with anti-CHERP pAb (Fig. 3b). Thapsigargin treatment induced enhancement of nuclear mCherry-ALG-2 signals in a speckled pattern, and these speckled signals of mCherry-ALG-2 partially merged with those of SGFP2-CHERP (Fig. 4C, panels g and h, and supplemental Movie S2). No significant alteration of SGFP2-CHERP was observed after stimulation with thapsigargin (Fig. 4D).

Arg/Ser-rich Region in CHERP Is Constitutively Phosphorylated—
An RS domain is defined as a region of at least 50 amino acids with >40% Arg/Ser content characterized by consecutive Arg-Ser or Ser-Arg dipeptide repeats (28). CHERP has a similar Arg/Ser-rich region (718–817) and the dipeptides span 737–817 amino acids with 25 repeats (62% RS content). The RS Arg/Ser-rich region (718–817) and the dipeptides span 737–817 amino acids with 25 repeats. The remaining PRR within GFP-CHERP CID was co-immunoprecipitated equally well in the presence of 10 μM CaCl2 but not in the presence of 5 mM EGTA. We performed a complementary co-immunoprecipitation assay with anti-pol II for immunoprecipitation and detected CHERP in the immunoprecipitates (Fig. 6B). ALG-2 was also co-immunoprecipitated with anti-pol II pAb but only in the presence of CaCl2.

PRR of CHERP Associates with RNA Polymerase II—Next, we examined whether the database-annotated CID of CHERP is essential for interaction between CHERP and RNA pol II by expressing various deletion mutants of GFP-CHERP and carrying out immunoprecipitation with anti-pol II pAb, followed by WB with anti-GFP mAb. As shown in Fig. 7, unexpectedly, GFP-CHERP ΔCID was co-immunoprecipitated equally well in comparison with GFP-CHERP FL. The remaining PRR within GFP-CHERP ACID is likely responsible for the binding, because the PRR of CHERP alone was sufficient for the association with RNA pol II, whereas the deletion of the PRR (GFP-CHERP ΔPRR) failed to bind to RNA pol II.

We further investigated the state of complex formation of GFP-CHERP deletion mutants by size-exclusion chromatography. As shown in Fig. 8A, the results revealed that a majority of the GFP fusion protein of the full-length was eluted at ~163 kDa, slightly greater than the molecular mass of monomeric protein calculated from the amino acid sequence (132.7 kDa, Table 2). A second peak appeared faster (>669 kDa), suggesting that some portion of CHERP population exists in an aggregate oligomeric form or in a complex with other proteins, probably including RNA pol II and RNA processing factors. GFP-CHERP ΔCID also exhibited peaks corresponding to a monomeric form.
Because a single band of the expected size was observed by Western blotting (Fig. 8B), the appearance of additional multiple peaks of smaller molecular masses suggests a higher susceptibility of the deletion mutant to proteolysis during the analytical size-exclusion chromatography that was performed at room temperature. GFP-
ChERP ΔRS was eluted at ~172 kDa, slightly greater than a monomeric form (121.5 kDa). GFP-CHERP-PRR (68 kDa) was eluted at ~81 kDa. In contrast, GFP-CHERP ΔPRR was exclusively eluted at higher molecular masses (>669, 395, and 204 kDa in an approximate peak height ratio of 3:11:8) than the monomeric form (93 kDa), suggesting occurrence as an aggregate oligomeric form or in a complex with other proteins. Effects of deletions in CHERP displayed a different pattern in the size-exclusion chromatography, suggesting that each region has a different structural role in protein-protein interactions. Although the PRR itself is likely to be sufficient for interaction with pol II, potential misfolding of the GFP-CHERP proteins caused by deletion should be also considered, and we cannot exclude the possibility that other regions, including CID, also have the capacity to interact with pol II independently of the PRR.

**CHERP Knockdown Increases Inclusion of Exons 41 and 42 in** \( IP_{3}R1 \) **Pre-mRNA—** CHERP was first identified as a modulator of the \( IP_{3} \) receptor and was shown to regulate \( Ca^{2+} \) homeostasis (19, 20). Because CHERP localizes partly at nuclear speckles, contains the phosphorylated RS domain, and interacts with RNA pol II, we speculated that abnormality in \( Ca^{2+} \) homeostasis caused by CHERP depletion in the previous reports might have been due to indirect effects of nuclear events. Hence, in this study, we analyzed the roles of CHERP and ALG-2 on alternative splicing of pre-mRNAs of \( Ca^{2+} \)-related proteins. \( IP_{3}R1 \) has three segments (S1, S2, and S3) that are reported to be variable in the splicing variants (39–41). S2 corresponds to exons 40–42. To investigate whether knockdown of CHERP causes changes in a splicing pattern of variable segments of S2 in \( IP_{3}R1 \) pre-mRNA, we performed RT-PCR using total RNA obtained from HT1080 cells that were transfected with siRNAs targeting CHERP (siCHERP.1 and .2) or negative control siRNA (NC) and with the use of S2-specific primers 1F and 1R (see Fig. 9A). Amplicons that skip exons 40–42 were exclusively produced from cells of mock transfection (data not shown) and NC siRNA, and amplicons that lack only exon 40 (△E40) or both exons 40 and 41 (△E40/41) were increased by transfection with siCHERP.1 and siCHERP.2 compared with
FIGURE 8. Size-exclusion chromatography profiles of GFP-fused CHERP deletion mutants. A, HEK293T cells transiently expressing indicated GFP-fused CHERP deletion mutants were lysed, and cell extracts treated with RNase A were resolved by size-exclusion chromatography. The GFP signals derived from each GFP-CHERP deletion mutant were monitored with a fluorescence detector. A number indicated on the top of each GFP signal peak stand for the retention time.

The positions of molecular mass standards (in kilodaltons, kDa) are indicated in the panel for control (No transfection). B, cell extracts used for A were analyzed by WB with anti-GFP mAb.
NC (Fig. 9B). No significant alteration of splicing patterns was observed in the S1 and S3 segments (data not shown). To further quantitatively analyze the effects of knockdown of CHERP or ALG-2 on alternative splicing in S2, we performed reverse transcription qPCR using each isoform-specific primer, which corresponds to the splicing junction sequence (Fig. 9A). Transfection of HT1080 cells with siCHERP.1 or siCHERP.2 reduced the level of CHERP mRNA to ~25% as shown in the lower panel of Fig. 9C. We observed statistically significant increases in percentage of isoforms ΔE40 and ΔE40/41 in CHERP knockdown cells compared with the control (percentage of ΔE40: NC, 0.0410 ± 0.0063; siCHERP.1, 0.659 ± 0.149; siCHERP.2, 0.506 ± 0.0625; percentage of ΔE40/41: NC, 1.16 ± 0.0820; siCHERP.1, 4.60 ± 0.597; siCHERP.2, 4.64 ± 0.579) (Fig. 9C, upper panel). Likewise, increases in ΔE40 and ΔE40/41 were observed (percentage of ΔE40: NC, 0.0434 ± 0.00440; siALG-2.1, 0.186 ± 0.0242; siALG-2.4, 0.288 ± 0.0367; percentage of ΔE40/41: NC, 1.11 ± 0.114; siALG-2.1, 2.16 ± 0.199; siALG-2.4, 2.65 ± 0.227) (Fig. 9D, upper panel) in ALG-2 knockdown cells, in which ALG-2 mRNA was reduced to less than 20% of the negative control (Fig. 9D, lower panel).

**TABLE 2**
Size-exclusion chromatography analyses of GFP-fused CHERP deletion mutants

| Sample         | M<sub>r</sub> (×10<sup>4</sup>) | Peak retention time | Peak height (>100) | Calculated M<sub>r</sub> (×10<sup>4</sup>) |
|----------------|---------------------------------|---------------------|--------------------|------------------------------------------|
| GFP            | 29                              | min                 | 11.039             | 131,836 42.9                              |
| GFP-CHERP FL   | 132.7                           | 6.795               | 463                | >669                                     |
|                |                                 | 8.385               | 247                | 315.9                                    |
|                |                                 | 9.263               | 1497               | 163.3                                    |
|                |                                 | 10.929              | 357                | 46.6                                     |
| GFP-CHERP DCID | 116                             | 6.298               | 118                | >669                                     |
|                |                                 | 9.578               | 345                | 128.8                                    |
|                |                                 | 10.29               | 615                | 75.4                                     |
|                |                                 | 10.91               | 330                | 47.3                                     |
| GFP-CHERP DPRR | 93                              | 7.169               | 3376               | >669                                     |
|                |                                 | 8.087               | 11116              | 395.3                                    |
|                |                                 | 8.966               | 8086               | 204.1                                    |
|                |                                 | 11.008              | 145                | 44.0                                     |
| GFP-CHERP DRS  | 121.5                           | 7.174               | 1168               | >669                                     |
|                |                                 | 8.276               | 1708               | 342.9                                    |
|                |                                 | 9.195               | 20,076             | 171.8                                    |
| GFP-CHERP PRR  | 68                              | 8.979               | 201                | 202.1                                    |
|                |                                 | 10.198              | 1832               | 80.8                                     |
|                |                                 | 11.003              | 1223               | 44.1                                     |

**Nuclear ALG-2 and CHERP in Alternative Splicing**

CHERP was first identified as an ER-localizing protein that modulates the IP<sub>3</sub> receptor (19, 20). Lin-Mosher et al. (25) recently re-investigated the subcellular localization of CHERP and concluded that CHERP is a nuclear protein, and they identified four NLS as follows: one in the boundary of the RS domain, two within the RS domain, and one near the C terminus. We also observed predominant nuclear localization of endogenous CHERP in several types of cells, including HeLa, HEK293, HT1080, and Jurkat cells by immunostaining with a specific antibody (Fig. 3, data not shown). GFP-fused CHERP, fused at the N or C terminus, also showed nuclear localization by fluorescence microscopic analysis (Fig. 2 and data not shown). Although immunostaining with a commercially available monoclonal antibody against CHERP also showed predominant nuclear localization of CHERP, it displayed weak signals of CHERP throughout the cytoplasm (data not shown). Expression of GFP-CHERP ΔRS resulted in partial distribution of the mutant in the cytoplasm (Fig. 2C). Interestingly, a fraction of cytoplasmic GFP-CHERP ΔRS co-localized with Sec31A (Fig. 2D), a COPII component, which is found co-localized with ALG-2 at ER exit sites (11, 12). We found that CHERP is phosphorylated and is recognized by a monoclonal antibody against pan-SR proteins with phosphorylated RS domains (Fig. 5). A recent study has indicated that CHERP is likely to be a substrate of SRPK1 and SRPK2 (42), which are SR-specific protein kinases and control nuclear entry and speckle formation of SR proteins (29). CHERP may shuttle between the nucleus and the cytoplasm under regulation by serine-arginine protein kinases. Because an ALG-2 dimer has the capacity to bridge two different interacting proteins as a Ca<sup>2+</sup>-dependent adaptor (31), CHERP may have an intrinsic property of association with the ER membrane through the ALG-2-Sec31A complex under certain physiological or nonphysiological conditions, including *in vitro* biochemical experiments.

In the protein database of UniProt, CHERP is also designated SR-related RNA polymerase II CTD-associated factor 6 (SCAF6) as an alternative name, and it has been assigned to contain a CID (a CTD-interacting domain). The CID of RBM16/SCAF8 was previously shown to bind to the phosphorylated form of the CTD of pol II (43). The CID of CHERP exhibits a lower degree of similarity with SCAF4 (31% identity) and with SCAF8 (26% identity) than the similarity (81% identity) between SCAF8 and SCAF4 at the primary structural level, and it remains to be clarified whether CHERP binds to the CTD of pol II directly. Some SR proteins interact with pol II directly or via nascent pre-mRNAs and function in coupling transcription to splicing (44). Because CHERP does not have an RRM common to SR proteins, CHERP might associate with RNA via interacting with other proteins that possess RNA-binding motifs such as SR140, a potential interacting protein of CHERP (25). Results of our preliminary experiments showed that another RRM-containing protein, SCAF4, was also co-immunoprecipitated with an antibody against CHERP (data not shown). However, we cannot com-
completely rule out the possibility of direct interaction between CHERP and RNA. Because the PRR of CHERP is well conserved in vertebrates (data not shown), it might have a functional role in protein-protein or protein-RNA interactions in addition to the presence of the direct binding sites for ALG-2 and direct or indirect binding sites for RNA pol II.

In contrast to the punctate distribution of CHERP and SC35 at the nuclear speckles, nuclear ALG-2 showed a diffuse pattern by immunofluorescence microscopic analysis (Fig. 3). Pre-permeabilization of cells with digitonin before fixation, however, enhanced the relative signal intensity of ALG-2 at nuclear speckles, probably due to washing out of nucleoplasmic free ALG-2 through nuclear pores but anchoring of ALG-2 to speckles via association with speckle components (Fig. 3). We demonstrated thapsigargin-induced Ca\(^{2+}\)-dependent transient accumulation of ALG-2 at the nuclear speckles by time-lapse live-cell imaging (Fig. 4 and supplemental Movies S1 and S2). SGFP2-ALG-2 co-localized with mCherry-fused splicing factor 3A subunit 2 (SF3A2), which is a component of U2 small nuclear ribonucleoprotein (supplemental Movie S3). An increase in nuclear Ca\(^{2+}\) caused no obvious change in nuclear speckle accumulation of CHERP and SF3A2, indicating that Ca\(^{2+}\)/ALG-2 is not essential for sub-nuclear localization of these proteins. Knockdown of CHERP by siRNA did not abolish the Ca\(^{2+}\)-dependent accumulation of ALG-2 (data not shown). It remains unknown whether depletion of CHERP by the siRNA method was merely insufficient or whether ALG-2 associates with other nuclear speckle-localizing proteins in addition to CHERP. Studies are in progress to search for additional nuclear proteins that associate with ALG-2 in a Ca\(^{2+}\)-dependent manner.

RBM22, a spliceosome-associated RNA-binding protein, was previously shown to induce translocation of ALG-2 from the cytoplasm to the nucleus by overexpression experiments, and interaction with ALG-2 was proposed (45). RBM22 contains the sequence \(5\tttPPPPPPG\)\(^{379}\), which matches with an ALG-2-binding motif type 2. We previously reported that GFP-RBM22...
showed a strong signal by far Western blot analysis with biotin-labeled ALG-2 but that GFP-RBM22 was not pulled down with GST-ALG-2 in the presence of Ca$^{2+}$, suggesting that RBM22 exists in a form inaccessible to ALG-2, for instance tightly bound with RNA, in the cell (18). In this study, we also performed live-cell imaging of GFP-RBM22 (supplemental Movie S4), but this protein showed relatively diffuse nucleoplasmic localization in accordance with the previous report (45). Co-localization at the nuclear speckles with ALG-2 after Ca$^{2+}$ stimulation was not evident for RBM22. RBM22 is evolutionarily conserved, and human RBM22 as well as the yeast ortholog Cwc2 have recently been shown to function in a catalytic center of the spliceosome by making contact with catalytically important RNA elements, including the U6 internal stem-loop and regions of U6 and the pre-mRNA intron near the 5′ splice site (46). However, CHERP is not found in fungi, and PRRs are lacking in the CHERP proteins from Caenorhabditis elegans and Drosophila, suggesting that Ca$^{2+}$-dependent interaction between CHERP and ALG-2 is a unique phenomenon in vertebrates.

Variants of IP$_3$R1 contain or lack three alternatively spliced exons (S1, S2, and S3), and expression of variants is regulated in a tissue-specific and temporally specific manner (39, 40, 47). The S2-containing form is predominant in neurons and absent from peripheral tissues (48). S2 is located between the two PKA phosphorylation sites, and alternative splicing of S2 is thought to contribute to the susceptibility of IP$_3$R1 to phosphorylation by PKA (39, 49), but the major effect of alternative splicing of IP$_3$R1 pre-mRNA on its physiological functions is still unknown. The levels of the alternatively spliced transcripts of IP$_3$R1 mRNA generated by the knockdown of CHERP or ALG-2 were very low compared with the major ΔE40/41/42 transcript (Fig. 9, B–D). Alternatively spliced isoforms might have differences in sensitivities against post-translational modifications or have much longer half-lives, and they contribute to the altered IP$_3$R1 functions more than the apparent mRNA levels. It would be interesting to know whether the degree of knockdown effects of CHERP or ALG-2 on alternative splicing is different in cell lines and cells at different developmental stages. We investigated the effects of CHERP knockdown on alternative splicing of other pre-mRNAs that encode proteins involved in Ca$^{2+}$ homeostasis regulation, including sarcoplasmic reticulum Ca$^{2+}$-ATPase 1 (SERCA1) and CRACR2A, but no significant changes were observed in these pre-mRNAs (data not shown). Decrease in the CHERP mRNA by the antisense method induced growth arrest in HEL cells (20). In addition to IP$_3$R1 pre-mRNA, CHERP and ALG-2 may have proper targets of pre-mRNAs for proteins that regulate cell growth, proliferation, and Ca$^{2+}$ mobilization.

Ca$^{2+}$-dependent alternative splicing has been shown for pre-mRNAs of several proteins, including BK channel slo, IP$_3$R1, plasma membrane Ca$^{2+}$-ATPase, neurexin IIa, and NMDA receptor 1 (50–54). Ca$^{2+}$/calmodulin-dependent protein kinase IV, a calmodulin-dependent kinase, is involved in alternative splicing influenced by Ca$^{2+}$ elevation that is triggered by depolarization in neuronal cells (47, 50). Identification of CHERP as an ALG-2-interacting protein and as a splicing modulator in this study has added new players in the Ca$^{2+}$-dependent alternative splicing system and should contribute to an understanding of the sophisticated post-transcriptional regulation in mammalian cells.

Acknowledgments—We thank Dr. Seiji Masuda (Kyoto University) for valuable suggestions. We also thank Keiko Yamamoto for technical assistance.

REFERENCES

1. Vito, P., Lacanà, E., and D’Adamo, L. (1996) Interfering with apoptosis: Ca$^{2+}$-binding protein ALG-2 and Alzheimer’s disease gene ALG-3. Science 271, 521–525
2. Rao, R. V., Poksay, K. S., Castro-Obregon, S., Schilling, B., Row, R. H., del Rio, G., Gibson, B. W., Ellerby, H. M., and Bredesen, D. E. (2004) Molecular components of a cell death pathway activated by endoplasmic reticulum stress. J. Biol. Chem. 279, 177–187
3. Draeby, L., Woods, Y. L., la Cour, J. M., Mollerup, J., Bourdon, J. C., and Berchtold, M. W. (2007) The calcium binding protein ALG-2 binds and stabilizes Scotin, a p53-inducible gene product localized at the endoplasmic reticulum.
Nuclear ALG-2 and CHERP in Alternative Splicing

protein (CHERP): regulated expression of antisense cDNA depletes CHERP, inhibits intracellular Ca\textsuperscript{2+} mobilization and decreases cell proliferation. Biochem. J. 348, 189–199

21. O’Rourke, F. A., LaPlante, J. M., and Feinstein, M. B. (2003) Antisense-mediated loss of calcium homeostasis endoplasmic reticulum protein (CHERP; ERPOT213–21) impairs Ca\textsuperscript{2+} mobilization, nuclear factor of activated T-cells (NFAT) activation and cell proliferation in Jurkat T-lymphocytes. Biochem. J. 373, 133–143

22. Ryan, T., Sharma, P., Ignatchenko, A., MacLennan, D. H., Kislenger, T., and Gramolini, A. O. (2011) Identification of novel ryamide receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP). J. Biol. Chem. 286, 17060–17068

23. Will, C. L., Uralb, H., Achs, T., Gentzel, M., Wilms, M., and Lührmann, R. (2002) Characterization of novel SF3b and 172 U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 21, 4978–4988

24. Saitoh, N., Spaht, C. S., Patterson, S. D., Bubulya, P., Neuwald, A. F., and Spector, D. L. (2004) Proteomic analysis of interchromatin granule clusters. Mol. Biol. Cell 15, 3876–3890

25. Lin-Mosher, Y., Sebastian, P. J., Higgins, L., Sampson, N. D., Hewitt, J. E., and Marchant, J. S. (2013) Re-evaluation of the role of calcium homeostasis endoplasmic reticulum protein (CHERP) in cellular calcium signaling. J. Biol. Chem. 288, 355–367

26. Fu, X. D., and Maniatis, T. (1992) The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3′ splice site. Proc. Natl. Acad. Sci. U.S.A. 89, 1725–1729

27. Zahler, A. M., Lane, W. S., Stolk, J. A., and Roth, M. B. (1992) SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev. 6, 837–847

28. Manley, J. L., and Krainer, A. R. (2010) A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). Genes Dev. 24, 1073–1074

29. Ghosh, G., and Adams, J. A. (2011) Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J. 278, 587–597

30. Kremers, G. J., Goedhart, J., van den Heuvel, D. J., Gerritsen, H. C., and Sittler, R. (2002) Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. Biochem. J. 355–367

31. Okumura, M., Ichioka, F., Kobayashi, R., Suzuki, H., Yoshida, H., Sibata, H., and Maki, M. (2009) Penta-EF-hand protein ALG-2 functions as a Ca\textsuperscript{2+}-dependent adaptor that bridges Alix and TSG101. Biochem. Biophys. Res. Commun. 386, 237–241

32. Zhao, Y., Araki, S., Wu, J., Teramoto, T., Chang, Y. F., Nakano, M., Abdelfattah, A. S., Fujiwara, M., Ishihara, T., Nagai, T., and Campbell, R. E. (2011) An expanded palette of genetically encoded Ca\textsuperscript{2+} indicators. Science 333, 1888–1891

33. Osugi, K., Shibata, H., and Maki, M. (2013) Biochemical and immunological detection of physical interactions between penta-EF-hand protein ALG-2 and its binding partners. Methods Mol. Biol. 963, 187–200

34. Spector, D. L., and Lamond, A. I. (2011) Nuclear speckles. Cold Spring Harb. Perspect. Biol. 3, pii: a000466

35. La Cour, J. M., Mollerup, J., and Berchtold, M. W. (2007) ALG-2 oscillates in subcellular localization, untemporally with calcium oscillations. Biochem. Biophys. Res. Commun. 353, 1063–1067

36. Neugebauer, K. M., and Roth, M. B. (1997) Distribution of pre-mRNA splicing factors at sites of RNA polymerase II transcription. Genes Dev. 11, 1148–1159

37. Mathew, R., Hartmuth, K., Möhlmann, S., Urlaub, H., Ficner, R., and Lühmann, R. (2008) Phosphorylation of human PRP28 by SRPK2 is required for integration of the U4/U6-U5 tri-snRNP into the spliceosome. Nat. Struct. Mol. Biol. 15, 435–443

38. Muñoz, J. M., de la Mata, M., and Kornbluth, A. R. (2010) The carboxy terminal domain of RNA polymerase II and alternative splicing. Trends Biochem. Sci. 35, 497–504

39. Danoff, S. K., Ferris, C. D., Donath, C., Fischer, G. A., Munemitsu, S., Ullrich, A., Snyder, S. H., and Ross, C. A. (1991) Inositol 1,4,5-trisphosphate receptors: distinct neuronal and nonneuronal forms derived by alternative splicing differ in phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 88, 2951–2955
40. Nakagawa, T., Shiota, C., Okano, H., and Mikoshiba, K. (1991) Differential localization of alternative spliced transcripts encoding inositol 1,4,5-trisphosphate receptors in mouse cerebellum and hippocampus: in situ hybridization study. *J. Neurochem.* 57, 1807–1810

41. Nuñoforá, F. C., Jr., Li, S. H., Danoff, S., Ullrich, A., and Ross, C. A. (1995) Molecular cloning of a cDNA for the human inositol 1,4,5-trisphosphate receptor type 1, and the identification of a third alternatively spliced variant. *Brain. Res. Mol. Brain Res.* 32, 291–296

42. Varjosalo, M., Keskitalo, S., Van Droge, A., Nurkkala, H., Vichalkovski, A., Aebersold, R., and Gstaiger, M. (2013) The protein interaction landscape of the human CMGC kinase group. *Cell Rep.* 3, 1306–1320

43. Becker, R., Loll, B., and Meinhart, A. (2008) Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the carboxyl-terminal domain of RNA polymerase II. *J. Biol. Chem.* 283, 22659–22669

44. Das, R., Yu, J., Zhang, Z., Gygi, M. P., Krainer, A. R., Gygi, S. P., and Reed, R. (2007) SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. *Mol. Cell* 26, 867–881

45. Montavill, P., Dai, Y., Cheung, C. Y., Giller, K., Becker, S., Michalak, M., Webb, S. E., Miller, A., and Krebs, J. (2006) Nuclear translocation of the calcium-binding protein ALG-2 induced by the RNA-binding protein RBM22. *Biochim. Biophys. Acta* 1763, 1335–1343

46. Rasche, N., Dybkov, O., Schnitzová, J., Akyildiz, B., Fabrizio, P., and Lührmann, R. (2012) Cwc2 and its human homologue RBM22 promote an active conformation of the spliceosome catalytic centre. *EMBO J.* 31, 1591–1604

47. Choi, J. Y., Beaman-Hall, C. M., and Vallano, M. L. (2004) Granule neurons in cerebellum express distinct splice variants of the inositol trisphosphate receptor that are modulated by calcium. *Am. J. Physiol. Cell Physiol.* 287, C971–C980

48. Schell, M. J., Danoff, S. K., and Ross, C. A. (1993) Inositol (1,4,5)-trisphosphate receptor: characterization of neuron-specific alternative splicing in rat brain and peripheral tissues. *Brain Res. Mol. Brain Res.* 17, 212–216

49. Wagner, L. E., 2nd, Li, W. H., and Yule, D. I. (2003) Phosphorylation of type-1 inositol 1,4,5-trisphosphate receptors by cyclic nucleotide-dependent protein kinases: a mutational analysis of the functionally important sites in the S2+ and S2− splice variants. *J. Biol. Chem.* 278, 45811–45817

50. Xie, J., and Black, D. L. (2001) A CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels. *Nature* 410, 936–939

51. Rozic-Kotliroff, G., and Zisapel, N. (2007) Ca2+/H11001-dependent splicing of neurexin IIa. *Biochem. Biophys. Res. Commun.* 352, 226–230

52. Li, Q., Lee, J. A., and Black, D. L. (2007) Neuronal regulation of alternative pre-mRNA splicing. *Nat. Rev. Neurosci.* 8, 819–831

53. Xie, J. (2008) Control of alternative pre-mRNA splicing by Ca2+/H11001 signals. *Biochim. Biophys. Acta* 1779, 438–452

54. Krebs, J., Groenendy, J., and Michalak, M. (2011) Ca2+/H11001-signaling, alternative splicing and endoplasmic reticulum stress responses. *Neurochem. Res.* 36, 1198–1211